StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck 2024 Restructuring Program by Quarter

2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M) ($M)

QuarterlyAnnual

Merck 2024 Restructuring Program: $162M in Q2 2026, up 24.6% from a year earlier.

Latest, Q2 2026
162
Period ended Jun 30, 2026
Change on a year earlier
+24.6%
130 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
6
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-07) ↗

Reported in Form 10-Q / 10-K Restructuring Footnote.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEnded2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026162+24.6%Form 10-Q (filed 2026-08-07) ↗
Q1 2026Mar 31, 2026148+41.0%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 2025216+15.5%Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 202588-68.5%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 2025130-26.6%Form 10-Q (filed 2026-08-07) ↗
Q1 2025Mar 31, 2025105-57.3%Form 10-Q (filed 2026-05-04) ↗
Q4 2024Dec 31, 2024187–Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 2024279–Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 2024177–Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 2024246–Form 10-Q (filed 2025-05-02) ↗

Breakdown

What makes up 2024 Restructuring Program

Cite this data

StockData. (2026). Merck 2024 Restructuring Program ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/restr-program2024-incurred

See every metric in the Merck KPI table. Data updated Oct 26, 2026.